{"id":948939,"date":"2020-01-14T17:20:32","date_gmt":"2020-01-14T16:20:32","guid":{"rendered":"https:\/\/frezzapartners.com\/?p=948939"},"modified":"2020-01-14T17:21:58","modified_gmt":"2020-01-14T16:21:58","slug":"biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer","status":"publish","type":"post","link":"https:\/\/frezzapartners.com\/en\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\/","title":{"rendered":"Biogen acquista da Pfizer un farmaco sperimentale in early-stage per l’Alzheimer"},"content":{"rendered":"

(Reuters) – Biogen Inc ha dichiarato luned\u00ec di aver accettato di acquistare un trattamento sperimentale in fase iniziale da Pfizer Inc che mira a testare in pazienti con malattia di Alzheimer e Parkinson.
\nIn base all’accordo, Pfizer otterr\u00e0 $ 75 milioni in anticipo.
\nBiogen ha dichiarato di voler sviluppare il candidato in fase iniziale per il trattamento della patologia Sundowning associata all’Alzheimer e al Disturbo del ritmo cardiaco del sonno irregolare (ISWRD) per i pazienti affetti dal morbo di Parkinson. La societ\u00e0 intende iniziare uno studio nel quarto trimestre.<\/p>\n

Il Sundowining \u00e8 un sintomo che colpisce il 20% o pi\u00f9 dei pazienti di Alzheimer che diventano confusi e ansiosi pi\u00f9 tardi nel corso della giornata, mentre ISWRD \u00e8 un disturbo del ritmo circadiano in cui i pazienti sperimentano un sonno frammentato durante la notte.
\n“Questa risorsa \u00e8 altamente complementare alla nostra pipeline esistente di potenziali terapie che modificano la malattia nelle malattie di Alzheimer e Parkinson”, ha detto Alfred Sandrock Jr., Chief Medical Officer di Biogen.<\/p>\n

Biogen ha eliminato lo sviluppo del suo farmaco sperimentale per l’Alzheimer, aducanumab, nel marzo dello scorso anno, e poi ha invertito il corso in ottobre, dicendo che prevedeva di presentare l’approvazione del farmaco negli Stati Uniti all’inizio del 2020, citando una nuova analisi dei dati.<\/p>\n

Le aziende hanno tentato e fallito per anni di sviluppare con successo un trattamento efficace per l’Alzheimer. Gli analisti di Wall Street stimano che aducanumab potrebbe raccogliere $ 4 miliardi di vendite annuali entro pochi anni dall’approvazione.<\/p>\n","protected":false},"excerpt":{"rendered":"

(Reuters) – Biogen Inc ha dichiarato luned\u00ec di aver accettato di acquistare un trattamento sperimentale in fase iniziale da Pfizer Inc che mira a testare in pazienti con malattia di Alzheimer e Parkinson. In base all’accordo, Pfizer otterr\u00e0 $ 75 milioni in anticipo. Biogen ha dichiarato di voler sviluppare il candidato in fase iniziale per il trattamento della patologia Sundowning associata all’Alzheimer e al Disturbo del ritmo cardiaco del sonno irregolare (ISWRD) per i pazienti affetti dal morbo di Parkinson….<\/p>\n","protected":false},"author":297440,"featured_media":948940,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[141],"tags":[],"class_list":["post-948939","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"yoast_head":"\nBiogen acquista da Pfizer un farmaco sperimentale in early-stage per l'Alzheimer - Frezza Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/frezzapartners.com\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen acquista da Pfizer un farmaco sperimentale in early-stage per l'Alzheimer - Frezza Partners\" \/>\n<meta property=\"og:description\" content=\"(Reuters) – Biogen Inc ha dichiarato luned\u00ec di aver accettato di acquistare un trattamento sperimentale in fase iniziale da Pfizer Inc che mira a testare in pazienti con malattia di Alzheimer e Parkinson. In base all’accordo, Pfizer otterr\u00e0 $ 75 milioni in anticipo. Biogen ha dichiarato di voler sviluppare il candidato in fase iniziale per il trattamento della patologia Sundowning associata all’Alzheimer e al Disturbo del ritmo cardiaco del sonno irregolare (ISWRD) per i pazienti affetti dal morbo di Parkinson....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/frezzapartners.com\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\/\" \/>\n<meta property=\"og:site_name\" content=\"Frezza Partners\" \/>\n<meta property=\"article:published_time\" content=\"2020-01-14T16:20:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-01-14T16:21:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/01\/BN-JN407_0723bi_P_20150723123352.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"749\" \/>\n\t<meta property=\"og:image:height\" content=\"499\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frezza Partners\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frezza Partners\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\\\/\"},\"author\":{\"name\":\"Frezza Partners\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"headline\":\"Biogen acquista da Pfizer un farmaco sperimentale in early-stage per l’Alzheimer\",\"datePublished\":\"2020-01-14T16:20:32+00:00\",\"dateModified\":\"2020-01-14T16:21:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\\\/\"},\"wordCount\":258,\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/01\\\/BN-JN407_0723bi_P_20150723123352.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\\\/\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\\\/\",\"name\":\"Biogen acquista da Pfizer un farmaco sperimentale in early-stage per l'Alzheimer - Frezza Partners\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/01\\\/BN-JN407_0723bi_P_20150723123352.jpg\",\"datePublished\":\"2020-01-14T16:20:32+00:00\",\"dateModified\":\"2020-01-14T16:21:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/frezzapartners.com\\\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/01\\\/BN-JN407_0723bi_P_20150723123352.jpg\",\"contentUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/01\\\/BN-JN407_0723bi_P_20150723123352.jpg\",\"width\":749,\"height\":499},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/frezzapartners.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen acquista da Pfizer un farmaco sperimentale in early-stage per l’Alzheimer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/\",\"name\":\"Frezza Partners\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/frezzapartners.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\",\"name\":\"Frezza Partners\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/en\\\/author\\\/fr3zz4partn3rs\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biogen acquista da Pfizer un farmaco sperimentale in early-stage per l'Alzheimer - Frezza Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/frezzapartners.com\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\/","og_locale":"en_US","og_type":"article","og_title":"Biogen acquista da Pfizer un farmaco sperimentale in early-stage per l'Alzheimer - Frezza Partners","og_description":"(Reuters) – Biogen Inc ha dichiarato luned\u00ec di aver accettato di acquistare un trattamento sperimentale in fase iniziale da Pfizer Inc che mira a testare in pazienti con malattia di Alzheimer e Parkinson. In base all’accordo, Pfizer otterr\u00e0 $ 75 milioni in anticipo. Biogen ha dichiarato di voler sviluppare il candidato in fase iniziale per il trattamento della patologia Sundowning associata all’Alzheimer e al Disturbo del ritmo cardiaco del sonno irregolare (ISWRD) per i pazienti affetti dal morbo di Parkinson....","og_url":"https:\/\/frezzapartners.com\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\/","og_site_name":"Frezza Partners","article_published_time":"2020-01-14T16:20:32+00:00","article_modified_time":"2020-01-14T16:21:58+00:00","og_image":[{"width":749,"height":499,"url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/01\/BN-JN407_0723bi_P_20150723123352.jpg","type":"image\/jpeg"}],"author":"Frezza Partners","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Frezza Partners","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/frezzapartners.com\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\/#article","isPartOf":{"@id":"https:\/\/frezzapartners.com\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\/"},"author":{"name":"Frezza Partners","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"headline":"Biogen acquista da Pfizer un farmaco sperimentale in early-stage per l’Alzheimer","datePublished":"2020-01-14T16:20:32+00:00","dateModified":"2020-01-14T16:21:58+00:00","mainEntityOfPage":{"@id":"https:\/\/frezzapartners.com\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\/"},"wordCount":258,"image":{"@id":"https:\/\/frezzapartners.com\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/01\/BN-JN407_0723bi_P_20150723123352.jpg","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/frezzapartners.com\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\/","url":"https:\/\/frezzapartners.com\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\/","name":"Biogen acquista da Pfizer un farmaco sperimentale in early-stage per l'Alzheimer - Frezza Partners","isPartOf":{"@id":"https:\/\/frezzapartners.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/frezzapartners.com\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\/#primaryimage"},"image":{"@id":"https:\/\/frezzapartners.com\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/01\/BN-JN407_0723bi_P_20150723123352.jpg","datePublished":"2020-01-14T16:20:32+00:00","dateModified":"2020-01-14T16:21:58+00:00","author":{"@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"breadcrumb":{"@id":"https:\/\/frezzapartners.com\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/frezzapartners.com\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/frezzapartners.com\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\/#primaryimage","url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/01\/BN-JN407_0723bi_P_20150723123352.jpg","contentUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/01\/BN-JN407_0723bi_P_20150723123352.jpg","width":749,"height":499},{"@type":"BreadcrumbList","@id":"https:\/\/frezzapartners.com\/biogen-acquista-da-pfizer-un-farmaco-sperimentale-in-early-stage-per-lalzheimer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/frezzapartners.com\/"},{"@type":"ListItem","position":2,"name":"Biogen acquista da Pfizer un farmaco sperimentale in early-stage per l’Alzheimer"}]},{"@type":"WebSite","@id":"https:\/\/frezzapartners.com\/#website","url":"https:\/\/frezzapartners.com\/","name":"Frezza Partners","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/frezzapartners.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0","name":"Frezza Partners","url":"https:\/\/frezzapartners.com\/en\/author\/fr3zz4partn3rs\/"}]}},"_links":{"self":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/948939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/users\/297440"}],"replies":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/comments?post=948939"}],"version-history":[{"count":0,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/948939\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media\/948940"}],"wp:attachment":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media?parent=948939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/categories?post=948939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/tags?post=948939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}